Hudock Inc’s Novo Nordisk NVO Stock Holding History

Hudock Inc’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$379K	Sell	10,003 -211	-2%	-$9.7K	0.05%	158
2026 Q2	$490K	Buy	+10,214	New	+$439K	0.06%	135
2025 Q3	–	Sell	-7,590	Closed	-$524K	–	203
2025 Q2	$524K	Sell	7,590 -141	-2%	-$9.6K	0.08%	103
2025 Q1	$537K	Buy	7,731 +2,423	+46%	+$200K	0.09%	89
2024 Q4	$457K	Buy	5,308 +2,743	+107%	+$297K	0.08%	104
2024 Q3	$305K	Sell	2,565 -727	-22%	-$97K	0.05%	131
2024 Q2	$470K	Buy	3,292 +64	+2%	+$8.48K	0.09%	95
2024 Q1	$414K	Buy	+3,228	New	+$384K	0.09%	92

Other funds holding NVO

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Nichols & Pratt Advisers Boston, Massachusetts $1.68B AUM 20.22% 1-Year Est. Return

Corda Investment Management Houston, Texas $1.52B AUM 30.53% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Philip James Wealth Mangement Milton, Georgia $906M AUM 30.39% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors New York $1.81B AUM 23.74% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Hudock Inc's NVO Position: Q3 2026 in Review

Hudock Inc reduced its Novo Nordisk (NVO) stake by 2.1% in Q3 2026, selling an estimated $9.7K and leaving 10,003 shares worth $379K. The position accounts for 0.05% of the portfolio, ranked #158.

Hudock Inc first reported a position in NVO in Q1 2024 and has held it in 8 quarters since. The position peaked at $537K in Q1 2025. 402 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Hudock Inc held 10,003 shares of Novo Nordisk worth $379K as of Q3 2026.
Hudock Inc sold 211 Novo Nordisk shares in Q3 2026, an estimated $9.7K.
Novo Nordisk made up 0.05% of Hudock Inc's portfolio in Q3 2026, its #158 holding.
Hudock Inc first reported a position in Novo Nordisk in Q1 2024 and has held it in 8 quarters since.
Hudock Inc's Novo Nordisk position peaked at $537K in Q1 2025.
402 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Hudock Inc's 13F filing for Q3 2026, filed 14 Oct 2026.